Process Analytical Technology-Based In-Line Buffer Dilution In Downstream Bioprocessing - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Process Analytical Technology-Based In-Line Buffer Dilution In Downstream Bioprocessing
The authors describe the operational requirements and design of a process-ready PAT-based IBD system.


Pharmaceutical Technology
Volume 34, pp. s18-s22

PAT-based in-line buffer dilution


Figure 2: A process analytical technology-based in-line buffer-dilution skid equipped with conductivity and pH process analyzers linked with a process feedback-control loop.
This article examines the operational requirements and design of a process-ready PAT-based in-line buffer-dilution (IBD) system, which is capable of making reproducible and accurate in-line buffer dilutions in concentrations as high as 100 × of the product using conductivity or pH feedback control. The technology can be used within stand-alone packaged equipment or engineered into a process-scale liquid chromatography skid. In the latter option, mobile phases are made on demand and sent directly to a process column for a sequence of chromatography steps in a purification regime. The comparison of a PAT-based and a mass-flow control system includes conductivity gradients, which are typical for biochromatographic processes, and the generation of linear pH gradients with good acidity control.


Figure 3: Piping and instrumentation diagram screen of a process analytical technology-based in-line buffer-dilution system.
The literature includes several examples of diluting buffers from concentrates in processes consistent with QbD (3). Some biopharmaceutical companies currently use a patented PAT-based IBD skid for buffer preparation and dilution (see Figure 2). To understand how IBD assists the QbD paradigm recommended by FDA, one should examine the basic technology platform. Figure 3 shows a sample piping and instrumentation diagram (P&ID) from the process-control screen of an IBD system.

A typical PAT-based IBD skid consists of three pumps labeled P001, P002, and P102. Deionized water for injection (WFI) is connected to P001, and buffer at concentrations as high as 100 × of the product is connected to P002. WFI and buffer concentrate are pumped into a blending loop, where the buffer concentrate is diluted to 1 × the product. The diluted buffer has a specific conductivity that can be analyzed by an in-line process conductivity sensor linked to a process-control feedback loop. The sensor continuously analyzes the conductivity of the buffer blend in the loop and sends an output signal to the process-control feedback loop. The loop then compares the current process conductivity value with a user-defined conductivity target set point for the buffer diluted to 1 × the product. Based on the feedback signal, the concentrate pump speeds can be increased or decreased. Whenever the acidity of the buffer solution must be adjusted, alkali or acid can be delivered from P102. In this instance, a pH probe would be installed in the blending loop and linked with its own process-control feedback loop to adjust the solution's pH to meet the user's specifications.

To assess the ability of a PAT-based IBD system to monitor a process and to actively manipulate it to maintain a desired state, the authors performed experiments to compare simple mass-flow and PAT-based control blending, and to reveal the true benefits of directly measuring the quantity of raw materials present during runs. The first experiment was a buffer-preparation scenario in which errors in the formulation of the concentrate raw material can cause an out-of-specification buffer-dilution product. The second comparison was made in the context of producing a linear pH gradient with pH adjustment and control not commonly available in a mass-flow-based dilution system.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
19%
To all process for new products only
14%
To select process for new products only
24%
To select processes for both new and legacy products
19%
Do not use QbD
24%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Global Biosimilars Market to Reach $2.445 Billion in 2013
Adapting to Change
AstraZeneca and Exco InTouch Collaborate to Augment Current COPD Pathways
Overcoming the Challenges in Biopharmaceutical Stability Testing
PhRMA Dismayed by Special 301 Report
FindPharma Custom Search
Source: Pharmaceutical Technology,
Click here